Fax: (775) 702-0963
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia
Results of Cancer and Leukemia Group B Study 19802
Version of Record online: 28 JUN 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 1, pages 90–98, 1 January 2013
How to Cite
Stock, W., Johnson, J. L., Stone, R. M., Kolitz, J. E., Powell, B. L., Wetzler, M., Westervelt, P., Marcucci, G., DeAngelo, D. J., Vardiman, J. W., McDonnell, D., Mrózek, K., Bloomfield, C. D. and Larson, R. A. (2013), Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. Cancer, 119: 90–98. doi: 10.1002/cncr.27617
- Issue online: 17 DEC 2012
- Version of Record online: 28 JUN 2012
- Manuscript Accepted: 23 MAR 2012
- Manuscript Revised: 13 MAR 2012
- Manuscript Received: 11 JAN 2012
Erratum: Erratum: Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD and Larson R A. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. Cancer. 2013;119:90-8.
Vol. 120, Issue 14, 2222, Version of Record online: 3 APR 2014
- adults with acute lymphoblastic leukemia;
- phase 2 study;
- dose intensification;
- central nervous system prophylaxis
Cancer and Leukemia Group B (CALGB) Study 19802, a phase 2 study, evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival (DFS) in adults with acute lymphoblastic leukemia (ALL) and whether high-dose systemic and intrathecal methotrexate could replace cranial radiotherapy for central nervous system (CNS) prophylaxis.
One hundred sixty-one eligible, previously untreated patients ages 16 to 82 years (median age, 40 years) were enrolled, and 33 (20%) were aged ≥60 years.
One hundred twenty-eight patients (80%) achieved complete remission (CR). Dose intensification of daunorubicin and cytarabine was feasible. At a median follow-up of 10.4 years for surviving patients, the 5-year DFS rate was 25% (95% confidence interval, 18%-33%), and the overall survival (OS) rate was 30% (95% confidence interval, 23%-37%). Patients aged <60 years who received the 80 mg/m2 dose of daunorubicin had a DFS of 33% (95% confidence interval, 22%-44%) and an OS of 39% (95% confidence interval, 29%-49%) at 5 years. Eighty-four patients (52%) relapsed, including 9 patients (6%) who had isolated CNS relapses. The omission of cranial irradiation did not result in higher than historic CNS relapse rates.
Intensive systemic, oral, and intrathecal methotrexate dosing permitted the omission of CNS irradiation in adult patients with ALL. This intensive approach using higher doses of daunorubicin and cytarabine failed to result in an overall improvement in DFS or OS compared with historic CALGB studies. Future therapeutic strategies for adults with ALL should be tailored to specific age and molecular genetic subsets. Cancer 2013. © 2012 American Cancer Society.